Related Experiment Video

Updated: Jan 7, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.3K

Copeptin as a prognostic biomarker in heart failure: a comprehensive review

Machineni Sravani1, Manickam Kokila1, Kasinathan Ramanathan1

  • 1Vinayaka Mission's Medical Colege & Hospital, Pondicherry, India.

Folia Medica
|December 30, 2025
PubMed

Insights

Copeptin, a biomarker reflecting vasopressin activity, shows promise in predicting heart failure (HF) outcomes. Elevated levels indicate higher mortality and hospitalizations, aiding risk stratification beyond traditional markers like BNP.

Area of Science:

  • Cardiology
  • Biomarker Research
  • Clinical Risk Stratification

Background:

  • Heart failure (HF) presents a significant global health challenge with high prevalence and poor prognosis.
  • Current biomarkers like B-type natriuretic peptides (BNP, NT-proBNP) are vital for HF diagnosis and risk assessment, yet limitations necessitate additional prognostic tools.
  • Copeptin, a marker of vasopressin system activity, has emerged as a potential prognostic indicator in HF management.

Purpose of the Study:

  • To review the physiological role of copeptin and its prognostic value in diverse heart failure phenotypes.
  • To explore the integration of copeptin into clinical risk models for enhanced heart failure prognostication.
  • To discuss challenges and future directions for copeptin's clinical adoption in heart failure management.

Main Methods:

  • Literature review synthesizing evidence on copeptin's physiological basis and clinical utility in heart failure.
  • Analysis of studies correlating copeptin levels with mortality, hospitalizations, and disease progression in acute and chronic HF.
  • Examination of copeptin's role in multimarker strategies and potential for guiding heart failure therapy.

Main Results:

  • Elevated copeptin levels are consistently associated with increased mortality, hospitalizations, and disease progression in heart failure patients.
  • Copeptin provides early detection of hemodynamic stress, complementing traditional biomarkers like BNP and NT-proBNP.
  • Evidence supports copeptin's utility in identifying high-risk HF patients, guiding treatment decisions, and monitoring disease trajectory.

Conclusions:

  • Copeptin is a valuable prognostic biomarker in heart failure, offering incremental predictive value beyond established markers.
  • Clinical adoption challenges include assay standardization, cost-effectiveness, and defining universally accepted cutoff values.
  • Future research focusing on copeptin-guided therapy, AI-driven models, and precision medicine may optimize heart failure management.

Keywords:
cardiovascular biomarkers copeptin heart failure prognostic biomarker vasopressin

More Related Videos

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

493
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.8K

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
511
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
658
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
281
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
195
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
430